No Data
No Data
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Krishna Vaddi Bought 4.3% More Shares In Prelude Therapeutics
Prelude Therapeutics CEO Makes Bold Stock Purchase
12 Health Care Stocks Moving In Friday's After-Market Session